Neogenomics Overview
Get informed when a big investor buys or sells
+ Follow97.56
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
Neogenomics (NEO) currently reports a PEG ratio of 97.56. That is above the Healthcare sector average of 12.15. Use the charts on this page to explore Neogenomics's PEG ratio history and peer comparisons.
Neogenomics's PEG ratio of 97.56 is higher than the Healthcare sector average of 12.15. That is roughly 702.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The PEG ratio is a valuation multiple that relates Neogenomics's market price to a fundamental measure such as earnings, sales, or book value. At 97.56, NEO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current PEG ratio of 97.56, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 12.15. From there, open related valuation or income-statement pages for Neogenomics, and consider following NEO for alerts when major investors trade the stock.
Neogenomics is classified in the Healthcare sector. On PEG ratio, it currently shows 97.56 versus a sector average near 12.15. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NEO with unrelated industries.
